Financial Shenanigans

The Forensic Verdict

Olectra's reported numbers are not flagrantly engineered, but the architecture around them — sales routed through promoter-controlled SPVs, a deconsolidated MSRTC vehicle, a CMD resignation just as that contract blew up, and contingent liabilities multiplying 87× in two years — pulls the forensic risk grade well above what the headline P&L suggests. We score the company Elevated (55/100): the auditor (Sarath & Associates) has issued an unmodified opinion with no material-weakness flag and DSO has compressed sharply, but the economics flow through a related-party plumbing system that the income statement alone cannot prove out. The single data point that would most change the grade is the FY26 audited related-party note: if EVEY-group sales as a share of revenue continues to expand and the SPV equity stakes keep growing without independent receivables aging, the grade should move to High.

13-Shenanigan Scorecard

Breeding Ground

Olectra's governance setup is not abusive on its face but it is structurally permissive: it sits inside a privately-held promoter empire (MEIL group) whose other entities are simultaneously its largest customer channel, a key supplier, a lender, and a shareholder. The board has formal independent oversight, but the promoter-side firepower around the audit committee is large.

The breeding-ground signal is loud on three fronts: promoter dominance, related-party intensity, and senior-management churn coinciding with a contract crisis (Maharashtra Transport Minister called for cancellation of the 5,150-bus deal in May 2025; CMD resigned a month later). Independent directors and an unqualified auditor opinion offset the picture but cannot neutralise it. The structural reality is that MEIL is parent, customer, supplier, lender, and now Chairman — every checkpoint flows through the same family.

Earnings Quality

Reported FY25 earnings are largely cash-backed and the gap between the income statement and the cash-flow statement is small once the long view is taken — but the composition of revenue is underwriting the entire forensic question.

The FY20 distortion (other income at 880% of operating profit) is historically resolved — operating profit is now self-supporting. Margins have expanded from a 7% trough (FY21) to 15% (FY25) as the e-bus delivery cadence scaled. ROCE of 21% in FY25 is consistent with a unit economics story rather than a manipulation story.

DSO has compressed from 658 days (FY20) to 140 days (FY25). On its own this is the single cleanest forensic test in the dataset — receivables grew 35% while revenue grew 56% in FY25, so the income statement is not running ahead of customer billings. Two caveats temper the read. First, the DSO improvement coincides with the rise of EVEY-group counterparties — collection from a related party is structurally easier than from a state transport undertaking. Second, an industrial OEM benchmark for DSO is closer to 60-90 days; 140 still leaves capital trapped in working capital relative to peers.

The contingent-liability move is the single most under-discussed forensic line item. Going from ₹6 cr to ₹540 cr in two years implies large bank guarantees, performance bonds, or letters of credit issued — likely tied to STU contracts and EV delivery commitments. The annual report does not disaggregate these adequately. If even a fifth crystallise in a downside scenario, that's ₹108 cr of off-balance-sheet exposure, more than 75% of FY25 net income.

Cash Flow Quality

Operating cash flow has been volatile but, in aggregate, real. The five-year sum of CFO (₹604 cr) outstrips the five-year sum of net income (₹328 cr) — a ratio of 1.84× that is unusual and reflects the working-capital release of FY21 (post-COVID inventory monetisation). Looked at narrowly over FY23-25, however, CFO of ₹274 cr almost exactly matches NI of ₹285 cr, and free cash flow turns negative.

FCF dropped to ₹-36 cr in FY25 despite ₹139 cr of net income because capex stepped up to ₹177 cr (versus depreciation of ₹37 cr). The Seetharampur Greenfield EV facility on 150 acres, partly funded by SBI term loan ₹500 cr and a MEIL unsecured loan of ₹150 cr (subordinated, repayable Mar-2031), is the principal absorber. CFO of the 9-month transcript shows working capital cycle improving to 42 days, but receivable position is "improving as our associate companies have got financial sanctions for the major projects" — i.e., CFO is materially driven by EVEY SPV financing, not end-customer payment.

FY23 is the period to interrogate. Net income of ₹67 cr was reported, CFO came in at ₹-10 cr. The gap was working-capital absorption (revenue scaling 84% YoY into a state-customer base). Management cleared the absorption in FY24 (CFO ₹143 cr) — but it took twelve months to convert. If FY26 follows the same pattern post the BEST-Mumbai dispute and CESL tender ramp, FCF could remain negative for another fiscal even on healthy P&L numbers.

Metric Hygiene

Olectra reports cleanly on GAAP-equivalent (Ind AS) lines and does not publish heavy non-GAAP adjustments. Where the forensic risk lives is in what management chooses to talk about — EBITDA margin and order book — versus what the cash and PBT lines tell the shareholder.

The compounding pattern in the metric panel is consistent: where management's framing is bullish (EBITDA margin, order book, working-capital days), the underlying line either has a transitory driver or is funded by related-party plumbing; where the line is honest about cyclicality (insulator margins, capex), the disclosure is also clean. The single piece of selective disclosure that matters most is the silence on contingent liabilities.

What to Underwrite Next

Five line items will move the forensic grade more than the rest of the model combined. Track them and adjust position size accordingly.

1. FY26 audited related-party note (Note 33). Track total RPT value as a share of consolidated revenue. The FY24 standalone disclosure already showed ₹57 cr of EVEY-Trans group sales; the FY26 ceiling under the postal-ballot resolutions is ~₹6,650 cr across EVEY entities. If actuals run materially below ceiling and the auditor again signs unmodified, the forensic grade can drift toward Watch. If actuals approach ceiling, the company is functionally a captive supplier to the MEIL group dressed as an OEM, and the grade should move to High.

2. Contingent-liability disclosure quality. ₹540 cr at FY25 with no breakdown by counterparty type. The next AR must disaggregate bank guarantees, performance bonds, and disputed claims. If disclosure quality does not improve, treat the entire ₹540 cr as a haircut to equity in stress scenarios.

3. EVEY SPV equity stakes and write-down risk. Investment line grew ₹110 cr → ₹730 cr FY24-25, with stakes of 1-26% in eight SPVs; carrying value at cost or equity method. The MSRTC stake was reduced 34% → 1% in FY25 — convenient timing relative to the May-2025 cancellation row. If any SPV impairs, both the investment line and the share-of-associate income line will re-rate.

4. CFO-conversion stability. FY25 CFO/NI was 1.0x but driven by payable stretch (DPO 172→181) and inventory drawdown (DIO 96→79). FY26 must convert at ≥0.7x without those tailwinds for the cash-flow story to be considered durable. If CFO/NI re-collapses to FY23 levels (-0.15x), the underlying P&L credibility weakens.

5. Senior-management stability. CMD K.V. Pradeep resigned 9-Jun-2025; PV Krishna Reddy (MEIL MD) became Chairman 5-Jul-2025; another SMP resignation flagged 3-Mar-2026; CFO B. Sharat Chandra remains. Track CFO and Whole-Time Director continuity through FY26 close — a third departure in 12 months is a forensic event by itself.

What would upgrade the grade to Watch (~30): three consecutive quarters of CFO/NI ≥0.8 without payable stretch; FY26 audited unmodified opinion with a clean ICFR; contingent liabilities decline or get disaggregated; EVEY-group RPT actuals run under ₹2,000 cr.

What would downgrade the grade to High (~70): another auditor change; an emphasis-of-matter on related parties; impairment on SPV investments; FY26 contingent liabilities crossing ₹1,000 cr; CFO and WTD both leaving inside 12 months; SEBI inquiry on the MSR-SPV deconsolidation.

The right way to use this work is as a position-sizing limiter and a valuation-multiple haircut, not a thesis-breaker. Olectra's accounting is not what fails — its insulation from a single counterparty bloc (the MEIL/EVEY/STU triangle) is what fails. A reader paying for an EV-OEM growth story would warrant a ~15-25% discount to peer EV/EBITDA multiples to compensate for the related-party plumbing and the contingent-liability surge that the income statement does not surface.